Neogenomics (NEO) Aktsia Kursus
Neogenomics Kursus
Viimase 19 aasta jooksul kasvas Neogenomics käive 28,2 % aastas ja jõudis 727,33 M USD-ni. Kasum aktsia kohta kasvas 50,4 % aastas viimase 8 aasta jooksul. Neogenomics netomarginaal −14,9 % on langenud võrreldes −1,7 %-ga mõni aasta tagasi. Neogenomics 12 kuu konsensuse hinnasiht on 19,00 USD, umbes üle kurssi 13,1 %. 16 analüütikust 11 soovitab osta — üldine konsensus on Osta.
Neogenomics aktsiahinnad
Hangi need andmed Eulerpool API kaudu
100 000 päringut/kuus tasuta · krediitkaarti pole
Neogenomics ärimudel ja aktsia analüüs
Korduma kippuvad küsimused Neogenomics aktsia kohta
Neogenomics Inc. (NYSE: NEO) is a leading provider of cancer-focused genetic testing services. The company's business model revolves around offering comprehensive testing solutions that aid in the diagnosis and treatment of cancer patients. Neogenomics Inc. operates through a network of laboratories and provides advanced molecular and cytogenetic testing, helping healthcare professionals make informed decisions based on genetic information. With a focus on precision medicine, Neogenomics Inc. delivers personalized treatment options, improving patient outcomes and delivering high-quality diagnostic services.
Neogenomics Inc is primarily active in the healthcare and diagnostic laboratory services industries.
The main competitors of Neogenomics Inc in the market are Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, and NeoGenomics Laboratories.
Neogenomics Inc is a leading provider of cancer-focused genetic testing services. Founded in 2001, the company is headquartered in Fort Myers, Florida. With an extensive network of laboratories across the United States, Neogenomics offers cutting-edge diagnostic and pharmaceutical services to aid in the personalized treatment and monitoring of various types of cancers. Over the years, Neogenomics has grown its portfolio of tests and services, catering to the evolving needs of healthcare professionals and patients. Their dedication to innovation and quality has positioned them as a trusted partner in the fight against cancer.
Some significant milestones achieved by Neogenomics Inc include its acquisition of Clarient Inc in 2015, which expanded its personalized medicine capabilities. The company also received full approval from the New York State Department of Health in 2017, allowing it to offer its services in all 50 states. Neogenomics Inc has strengthened its position in the molecular testing market through strategic collaborations with pharmaceutical companies. Furthermore, in 2019, the company completed its acquisition of Genoptix, enhancing its oncology diagnostics capabilities. These milestones demonstrate Neogenomics Inc's commitment to growth and innovation in the field of cancer diagnostics and personalized medicine.
Neogenomics Inc is primarily present in the United States.
Neogenomics Inc prides itself on its commitment to excellence and innovation in the field of precision medicine. With a strong corporate philosophy centered around patient care and advancing the fight against cancer, Neogenomics Inc places great importance on ethical practices and providing accurate diagnostic solutions. The company believes in fostering a collaborative environment to bring cutting-edge technologies and personalized medicine to patients globally. By constantly pushing boundaries and embracing transformative ideas, Neogenomics Inc aims to revolutionize how cancer is detected and treated. Through its dedication to quality, integrity, and patient-centric values, the company sets itself apart as a leader in the field.
Analüütikud määravad Neogenomics aktsiale keskmiseks hinnasihi 19,00 USD (mediaan: 19,00 USD), mis on +15,2 % viimase hinna suhtes. Konsensus põhineb 16 analüütiku hinnangul.
16 analüütikut hindavad praegu Neogenomics aktsiat: 11 soovitab osta, 5 hoida ja 0 müüa. 2026. aastaks ootavad analüütikud, et Neogenomics teenib tulu 805,18 M USD ja kasumit aktsia kohta 0,92 USD.
Praeguse kursiga kaubeldakse Neogenomics aktsiaga 15,02 EUR (16,80 USD) juures.
Neogenomics aktsia (NEO) on noteeritud 5 börsil, sh: NASDAQ (NEO), SIX (Zürich) (NG9.SW), Frankfurt (NG9.F), München (NG9.MU), Düsseldorf (NG9.DU).
Neogenomics Inc is a leading company in oncology diagnostics and offers a wide range of solutions and products to its customers. The company has been listed on the stock exchange since 2001 and is the largest provider of cancer diagnostics services in the United States. Translate the text to the best possible English.
oodatav Neogenomics käive on 805,18 M USD. See näitaja põhineb praegusel finantsandmetel ja peegeldab ettevõtte äritulemuseid.
oodatav Neogenomics kasum on 23,72 M USD. Netokasum peegeldab ettevõtte kasumlikkust pärast kõigi kulude mahaarvamist.
Võrdlusarvud hinna ja kasumiga (P/E) Neogenomics jaoks on praegu 18,22. P/E-suhtarv võrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata Neogenomics aktsia väärtust.
Kursuse ja müügimahu suhe (P/S) Neogenomics jaoks on praegu 0,54. P/S-suhtarv võrdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismõõdikuna Neogenomics aktsia jaoks.
Eulpooli kvaliteedinäitaja Neogenomics jaoks on 3/10.
Neogenomics ISIN on US64049M2098. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.
Neogenomics WKN on 120159. WKN (Wertpapierkennnummer) on kuuekohaline saksa väärtpaberi identifitseerimise number.
Neogenomics ticker on NEO. Ticker-sümbol kasutatakse Neogenomics aktsiate kauplemiseks börsil.
Neogenomics aktsia
Neogenomics konkurendid
Neogenomics Börsiticker
Neogenomics FIGI
Kõik teised näitajad ja analüüsid Neogenomics kohta sügavamalt
Meie Neogenomics-aktsia analüüs sisaldab olulisi finantsnäitajaid, nagu käive, kasum, P/E suhe, P/S suhe, EBIT, samuti teavet dividendi kohta. Lisaks käsitleme aspekte nagu aktsiad, turukapitalisatsioon, võlad, omakapital ja kohustused ettevõttes Neogenomics. Kui otsite nende teemade kohta põhjalikumat teavet, pakume teile meie alamlehtedel üksikasjalikke analüüse: